Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Melanoma Stage III: early-phase trial registry
10 of 16 indexed Melanoma Stage III trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 10 currently recruiting · #1,060 of 28,707 conditions by registered trial count
Melanoma Stage III: 16 US clinical trials tracked, 10 recruiting.
Melanoma Stage III is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is H. Lee Moffitt Cancer Center and Research Institute, running 3 of these trials.
Enrollment posture brief
Registry condition melanoma-stage-iii
OPEN 10 | RECR 63% | LATE 0 | EARLY 14 | RANK #1060 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Advanced Gastroesophageal Junction Adenocarcinoma (63% recruiting · 8 trials)
Melanoma Stage III lists 10 open slots (63% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Melanoma Stage III on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Melanoma Stage III is recruiting above its size-band peers.
10 of 16 indexed trials (62.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Melanoma Stage III research.
H. Lee Moffitt Cancer Center and Research Institute accounts for 3 of 16 trials (18.8%). 14 distinct sponsors appear on at least one study for this condition label.
-
Most Melanoma Stage III trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 16 trials that report a genuine target (sentinel values excluded). 12 of those (75%) plan for fewer than 100 participants.
-
Melanoma Stage III research is mostly interventional.
15 interventional and 1 observational studies make up this index (93.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
Perspective Therapeutics
NCT05655312
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Krystal Biotech
NCT05970497
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
Philogen S.p.A.
NCT06284590
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT06295159
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT04741997
Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma
Kelly McMasters
NCT04513028
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
NCT04562129
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
University of California, San Francisco
NCT04598009
Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients
University of Wisconsin, Madison
NCT06199713
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
University of California, Irvine
NCT06771544
SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
Syntrix Biosystems
NCT03161431
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
Abramson Cancer Center at Penn Medicine
NCT04013854
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
Diwakar Davar
NCT04139902
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
Massachusetts General Hospital
NCT04305145
CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma
Memorial Sloan Kettering Cancer Center
NCT05289193
A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
BioNTech SE
NCT04526899
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 10 |
Top Sponsors
Named interventions
Most-linked intervention names on Melanoma Stage III records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Melanoma Stage III trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Melanoma Stage III page
16 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Melanoma Stage III trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- H. Lee Moffitt Cancer Center and Research Institute sponsors the most Melanoma Stage III trials on record, review their full trial history before evaluating a specific study. See H. Lee Moffitt Cancer Center and Research Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Melanoma Stage III condition card totals 16 registered trials; most-linked intervention Nivolumab; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.